Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 36.16% is 50% above its 5-year average of 24.12%, near the high end of its 5-year range (-470.69%–53.67%).
12.50% below its 12-month average of 41.33%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 53.67%.
GROSS MARGIN
36.16%
GROSS MARGIN AVG TTM
41.33%
GROSS MARGIN AVG 3Y
28.93%
GROSS MARGIN AVG 5Y
24.12%
GROSS MARGIN AVG 10Y
5.24%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-12.50%
CURRENT VS 3Y AVG
+24.99%
CURRENT VS 5Y AVG
+49.93%
CURRENT VS 10Y AVG
+590.18%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 738 covered companies
CURRENT VS SECTOR MEDIAN
-11.00%
vs the sector median at left
Market Cap
$1.22B
Gross Margin
21.39%
TTM Avg
44.69%
3Y Avg
30.35%
5Y Avg
27.69%
Market Cap
$1.21B
Gross Margin
75.69%
TTM Avg
77.82%
3Y Avg
66.62%
5Y Avg
62.85%
Market Cap
$1.23B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.18B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.15B
Gross Margin
99.36%
TTM Avg
84.41%
3Y Avg
76.16%
5Y Avg
77.91%
Market Cap
$1.15B
Gross Margin
88.05%
TTM Avg
93.34%
3Y Avg
92.32%
5Y Avg
92.94%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.22B | 36.16% | 41.33% | 28.93% | 24.12% |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 21.39% | 44.69% | 30.35% | 27.69% |
| Omada Health (OMDA)vs › | $1.23B | 68.19% | 63.14% | 57.81% | 57.81% |
| MannKind Corporation (MNKD)vs › | $1.21B | 75.69% | 77.82% | 66.62% | 62.85% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.23B | 0.00% | 0.00% | 0.00% | 0.00% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.18B | 0.00% | 0.00% | 0.00% | 0.00% |
| Kardigan, Inc. (KARD)vs › | $1.27B | 0.00% | 0.00% | 0.00% | 0.00% |
| Nektar Therapeutics (NKTR)vs › | $1.15B | 99.36% | 84.41% | 76.16% | 77.91% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 88.05% | 93.34% | 92.32% | 92.94% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.14B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
36.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 53.67% |
| 2026-03-31 | 41.42% |
| 2025-12-31 | 17.73% |
| 2025-09-30 | 50.45% |
| 2025-06-30 | 43.35% |
| 2025-03-31 | 42.57% |
| 2024-12-31 | 35.67% |
| 2024-09-30 | 10.54% |
| 2024-06-30 | 22.68% |
| 2024-03-31 | 17.73% |
| 2023-12-31 | 8.00% |
| 2023-09-30 | 16.00% |
| 2023-06-30 | 16.29% |
| 2023-03-31 | 15.01% |
| 2022-12-31 | 5.72% |
| 2022-09-30 | 15.40% |
| 2022-06-30 | 20.01% |
| 2022-03-31 | 29.55% |
| 2021-12-31 | -470.69% |
| 2021-09-30 | -3.58% |
| 2021-06-30 | -101.04% |
| 2021-03-31 | -23.50% |
| 2020-12-31 | -87.40% |
| 2020-09-30 | -13.53% |
| 2020-06-30 | -29.57% |
| 2020-03-31 | -76.80% |
| 2019-12-31 | -275.15% |
| 2019-09-30 | -40.93% |
| 2019-06-30 | 40.77% |
| 2019-03-31 | 51.85% |
| 2018-12-31 | 6.69% |
| 2018-09-30 | 55.69% |
| 2018-06-30 | 186.94% |
| 2018-03-31 | 65.48% |
| 2017-12-31 | 190.99% |
| 2017-09-30 | -95.32% |
| 2017-06-30 | -62.76% |
| 2017-03-31 | -189.45% |
| 2016-12-31 | -19.13% |
| 2016-09-30 | -41.96% |
| 2016-06-30 | 101.83% |
| 2016-03-31 | 332.26% |
| 2015-12-31 | 79.42% |
| 2015-09-30 | 173.01% |
| 2015-06-30 | 157.31% |
| 2015-03-31 | 128.42% |
| 2014-12-31 | 112.21% |
| 2014-09-30 | 100.00% |
| 2014-06-30 | 100.00% |
| 2014-03-31 | 100.00% |
| 2013-12-31 | 100.00% |
| 2013-09-30 | 100.00% |
| 2013-06-30 | 0.00% |
